Reproducible cerebrospinal fluid proteomic signatures across early neuronal α-synuclein disease stages in PPMI
Parkinson's disease (PD) begins years before motor onset. Biomarkers are needed to detect early disease, stratify risk, and monitor progression. Through proximity extension assay profiling of the cerebrospinal fluid (CSF) proteome, we investigated early neuronal a-synuclein disease (NSD) in independent cohorts (discove...